Clinical trials: Head and Neck Neoplasm
Advanced Solid Tumors
Phase 1 Study of OSI-930 in Cancer Patients
Open label, phase 1, dose escalation
- Trial name
- NCT00513851
- Testing
- OSI-930
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable…
- Trial name
- NCT04220866
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Oesophageal Cancer, Oesophageal Disease
EndoVE endosCopic Treatment for Oesophageal and Gastric canceR
This project aims to establish the safety and efficacy of treating patients with inoperable oesophageal cancer or gastric cancer, using an endoscopic electroporation system (EndoVE) to facilitate direct chemotherapy tumour…
- Conditions
- Oesophageal Cancer, Oesophageal Disease, Gastric Cancer
- Trial name
- VECTOR (NCT04649372)
- Testing
- EndoVE
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Mirai Medical
Gastrointestinal Cancer
Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer
In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer.
- Trial name
- ENgAGE-HK (NCT04081831)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- Hong Kong
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Head and Neck Cancer, Oropharynx Cancer
Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
The purpose of this study is to evaluate the safety of adding the investigational drug Motexafin Gadolinium to the standard treatment of radiation therapy and chemotherapy with drugs called 5-FU and cisplatin in patients with…
- Conditions
- Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
- Trial name
- NCT00080028
- Testing
- Motexafin Gadolinium Injection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pharmacyclics LLC.
Solid Tumors Harboring NTRK Fusion
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- NAVIGATE (NCT02576431)
- Testing
- BAY2757556 (Larotrectinib, Vitrakvi)
- Where
- 98 sites in United States, Argentina and 23 more
- Volunteers
- 215 people
- Sponsor
- Bayer
Nasopharyngeal Carcinoma
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
The investigators do the clinical trial (patients with metastatic nasopharyngeal carcinoma treated with donafenib after failure of standard therapy) to assess safety and efficacy of donafenib in patients with metastatic…
- Trial name
- NCT02698111
- Testing
- Donafenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Head and Neck Neoplasms, Neoplasm Recurrence, Local
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent…
- Conditions
- Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT00401323
- Testing
- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU)
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 568 people
- Sponsor
- Sanofi
Esophageal Neoplasms
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
To determine the activity and efficacy of the schema specified as dose regimen To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
- Trial name
- NCT00259402
- Testing
- Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Sanofi
Solid Tumor, Colorectal Cancer
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
- Conditions
- Solid Tumor, Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07589205
- Testing
- Drug: IBI3028
- Where
- China
- Volunteers
- 493 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Esophageal Cancer
HPPH Photodynamic Therapy for Patients With Esophageal Cancer
Phase I study was to investigate the safety and tolerability of the photosensitizer (PS) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) for injection in patients with Esophageal Cancer.
- Trial name
- HPPH (NCT03757754)
- Testing
- HPPH 2.5 mg/m2, HPPH 3 mg/m2, HPPH 3.5 mg/m2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Advanced Head and Neck Cancer
P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer
The objectives of this study are to investigate the efficacy and safety of rAd-p53 gene combined with radio- and chemo-therapy vs.
- Trial name
- NCT02429037
- Testing
- rAd-p53, radiation, Cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Solid Tumors, Metastatic Melanoma
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3)…
- Conditions
- Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT03708328
- Testing
- Lomvastomig
- Where
- 17 sites in United States, Denmark and 4 more
- Volunteers
- 134 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2…
- Trial name
- NCT03116152
- Testing
- IBI308, paclitaxel/ irinotecan
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms
A Study of SGN-STNV in Advanced Solid Tumors
This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms
- Trial name
- NCT04665921
- Testing
- SGN-STNV
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 111 people
- Sponsor
- Seagen Inc.
Candidiasis, Oral, Thrush
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received…
- Conditions
- Candidiasis, Oral, Thrush, Candidiasis
- Trial name
- NCT00612963
- Testing
- Frio Oral Rinse
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Biomedical Development Corporation
Esophageal Cancer, Gastroesophageal Junction Cancer
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
The purpose of this study is to describe the real-world effectiveness and patterns of use of adjuvant nivolumab in adult participants with Stage II/III Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC) in China.
- Trial name
- NCT06499298
- Testing
- Nivolumab
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.